ABOS
Acumen·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 2
Consensus Rating "Strong Buy"
Bearish Engulfing
Ample Liquidity
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ABOS
Acumen Pharmaceuticals, Inc.
A clinical-stage biopharmaceutical company that developing novel targeted therapeutics for Alzheimer's disease
427 Park St., Charlottesville, VA 22902
--
Acumen Pharmaceuticals, Inc., was incorporated in Delaware in 1996. The company is a clinical-stage biopharmaceutical company that is developing a new disease-modifying approach to target what the company believes is a key root cause of Alzheimer's disease, or AD. Alzheimer's disease is a progressive neurodegenerative disease of the brain that causes loss of memory and cognitive function, and ultimately death.
Earnings Call
Q1/2025
Estimate EPS-0.55
Actual EPS-0.48
Estimate Revenue--
Actual Revenue0
Acumen Pharmaceuticals' Q1 2025: Key Contradictions in ALTITUDE Study and Strategic Outlook
May 20,2025 01:01
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS-0.46
Actual EPS-0.68
Estimate Revenue--
Actual Revenue0
Acumen Pharmaceuticals' Q2 2025: Key Contradictions in Alzheimer's Biomarker Strategies and Treatment Approaches
Aug 12,2025 02:53
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
ABOS has released its 2025 Q3 earnings. EPS was reported at -0.44, versus the expected -0.68, beating expectations. The chart below visualizes how ABOS has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
